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ABSTRACT
Objectives: Current evidence to support non-medical
prescribing is predominantly qualitative, with little
evaluation of accuracy, safety and appropriateness.
Our aim was to evaluate a new model of service for the
Australia healthcare system, of inpatient medication
prescribing by a pharmacist in an elective surgery
preadmission clinic (PAC) against usual care, using an
endorsed performance framework.
Design: Single centre, randomised controlled,
two-arm trial.
Setting: Elective surgery PAC in a Brisbane-based
tertiary hospital.
Participants: 400 adults scheduled for elective
surgery were randomised to intervention or control.
Intervention: A pharmacist generated the inpatient
medication chart to reflect the patient’s regular
medication, made a plan for medication perioperatively
and prescribed venous thromboembolism (VTE)
prophylaxis. In the control arm, the medication chart
was generated by the Resident Medical Officers.
Outcome measures: Primary outcome was
frequency of omissions and prescribing errors when
compared against the medication history. The clinical
significance of omissions was also analysed.
Secondary outcome was appropriateness of VTE
prophylaxis prescribing.
Results: There were significantly less unintended
omissions of medications: 11 of 887 (1.2%)
intervention orders compared with 383 of 1217
(31.5%) control (p<0.001). There were significantly
less prescribing errors involving selection of drug,
dose or frequency: 2 in 857 (0.2%) intervention orders
compared with 51 in 807 (6.3%) control (p<0.001).
Orders with at least one component of the prescription
missing, incorrect or unclear occurred in 208 of 904
(23%) intervention orders and 445 of 1034 (43%)
controls (p<0.001). VTE prophylaxis on admission to
the ward was appropriate in 93% of intervention
patients and 90% controls (p=0.29).
Conclusions: Medication charts in the intervention
arm contained fewer clinically significant omissions,
and prescribing errors, when compared with
controls. There was no difference in appropriateness
of VTE prophylaxis on admission between the two
groups.
Trial Registration: Registered with ANZCTR—ACTR
Number ACTRN12609000426280
ARTICLE SUMMARY
Article focus
▪ A doctor–pharmacist collaborative prescribing
model provides as least as high a quality of care
as usual care, with regard to safety, access,
appropriateness, effectiveness, efficiency and
consumer participation.
▪ Workforce shortages are prompting a review of
the way the current workforce is utilised, and
whether different roles could be taken on by
healthcare professionals to alleviate some of the
pressures within the system.
▪ Research on non-medical prescribing so far is
predominantly qualitative in nature. Our study
has analysed quantitative data on the safety,
accuracy and appropriateness of prescribing to
try and assess whether this model is at least as
good as usual care.
Key messages
▪ Pharmacists’ skills in medication management
are currently underutilised, and with appropriate
training and education they could be contributing
to medication management much more effect-
ively by taking on a prescribing role.
▪ The prescribing is collaborative and driven by
guidelines and under the supervision of a
medical team. Diagnosis is not within the scope
of practice of the prescribing pharmacist.
▪ This model of care has been proved to be highly
effective in this study, with an increased accur-
acy, safety and appropriateness of prescribing
within the intervention arm.
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INTRODUCTION
Prescribing involves four stages: information gathering,
clinical decision-making, communication of decision and
monitoring.1 Taking a medication history, continuing,
ceasing and withholding of medications and initiating new
medications are critical components of prescribing asso-
ciated with an admission for surgery. Medication errors are
common, occur most often at the time of prescribing, and
frequently on the day of hospital admission, resulting in dis-
crepancies between regular medications and admission
orders.2–4 A small, but significant, proportion of errors
result in adverse drug events (ADEs).5 Errors have been
defined as when there is “a failure to communicate essen-
tial information; the use of drugs or doses is inappropriate
for the individual patient; and transcription error.”6 To be
able to communicate a clinical decision safely and effect-
ively in the form of a written prescription, it is necessary to
select the correct drug, together with the route, form,
dose, frequency and duration.7 Multiple interventions have
been suggested in an attempt to improve prescribing, with
suggestions that increased training of the individual, a con-
trolled environment and a change in organisational
culture are necessary.8
Within hospital, the medication chart provides instruc-
tions for safe medication supply and administration,
and ensures the patient access to medications as an
inpatient. It is an integral part of communication
between doctors, pharmacists and nurses about prescrib-
ing decisions and is used as the primary source of infor-
mation regarding medications on discharge. The
pharmacy service in the Princess Alexandra Hospital
(PAH) preadmission clinic (PAC) began in 1998 to
provide timely, accurate and comprehensive information
about medication as patients crossed between healthcare
settings. It ensured accurate transfer of information at
admission, during the inpatient stay and at discharge,
the benefits of which were a reduction in both readmis-
sions and contact with community healthcare providers
postdischarge.9 The importance of accurate transfer of
information across the whole surgical care pathway from
preadmission to discharge, including information about
medications, has been highlighted in a recent study that
reported how communication failures led to patient
morbidity and mortality. Standardisation and systemisa-
tion of communication processes, along with other inter-
ventions targeted at the entire surgical pathway, were
recommended with a view to improving information
transfer and quality of care.10
Pharmacists in PACs have been shown to improve the
accuracy of medication histories and medication orders,
when compared with standard care, and the efficacy of
prescribing perioperatively in line with recognised guide-
lines.11 12 Only with an accurate history of medication
usage can decisions be made safely regarding the peri-
operative management of medications. Medication his-
tories are elicited from a variety of sources of
information: patient’s own medications, the patient or
carer, general practitioner summaries, community phar-
macies, previous hospital admissions and nursing home
records. A number of sources may be consulted to build
an accurate record of medication that the patient is
taking, both regularly and occasionally.
The range of prescribers has been expanded in a
number of countries, with changes in legislation to allow
for extension of prescribing privileges to non-medical
professionals, including pharmacists. The objective of
this was to make greater use of the skills and specialisa-
tion of pharmacists so that a more flexible system for the
prescribing, supply and administration of medicines
could be developed, while maintaining safe and appro-
priate access to medicines.13 14
In response to the documented workforce shortages
in Australia, Brooks et al described possible solutions,
including ‘task substitution’, and a focus has been
placed recently on non-medical prescribers within the
healthcare system.15–19 Pharmacists, with training in
pharmacology and therapeutics, are potentially well
placed to undertake prescribing roles. An Australian
study identified the main driver behind pharmacist pre-
scribing as the desire to work collaboratively with
medical and nursing staff to:
▸ Provide consumers with improved, responsible and
safe access to prescription medicines;
▸ Optimise use of pharmacists’ and doctors’ skills and
time;
▸ Reduce inefficient use of health resources.20
Evidence to support non-medical prescribing so far
has been mainly qualitative, with minimal evaluation of
access, safety and appropriateness. One recent review
concluded that acceptability of non-medical prescribing
services is based on the perceived value to the health
service.21 This lack of evidence has led to calls to prove
the safety and effectiveness of non-medical prescribing
services in Australia.22 The aim of the data analysis dis-
cussed in this paper was to compare a doctor—pharma-
cist collaborative prescribing model with usual care, with
regard to safety, access, appropriateness and effective-
ness; the null hypothesis being that no difference exists
between the two models of care.23
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The results with regard to the accuracy and safety of medica-
tion charts produced in the study are emphatic and statistically
significant.
▪ The intervention is reproducible in other settings with a
pharmacist of appropriate experience, training and education.
▪ The study assessed one pharmacist prescriber versus a cohort
of medical prescribers. While this has been accounted for in
the analysis, it also reflects what usual practice would be in a
model care such as this. The authors recognise and acknow-
ledge it as a limitation.
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METHODS
The study was conducted between June and September
2009 in the surgical PAC at PAH, a 750-bed tertiary
teaching hospital in Queensland.
The definition of error used in the study was: “a
failure to communicate essential information; the use of
drugs or doses is inappropriate for the individual
patient; and transcription error.”3
All patients who attended PAC and could provide
written informed consent were considered for participa-
tion. Patients were excluded if they were under 18 years
of age, unable to communicate due to language difficul-
ties or undergoing day surgery (see figure 1).
Patients were approached on arrival at the clinic and
written consent was obtained. After consent, patients
were randomised using a computer generated random-
isation list, in blocks of 10 (Microsoft Excel). Sealed
envelopes (not prepared by the recruiting researcher)
contained a zero or one as per the computer list; the
next envelope was opened after consent to determine
whether a patient entered the control or intervention
arm, respectively. If a patient had been randomised and
their surgery cancelled during PAC, the patient was
removed from the study and not replaced.
A previous pilot study in the PAC showed an error rate
of 12% of orders.24 Using an expected error rate of 8%
in the intervention arm, a sample size of 932 orders per
group was calculated to be required for a power of 80%.
Assuming an average of five orders per patient, approxi-
mately 200 patients per arm would be required.
Only one pharmacist in the PAC, with 3 years’ experi-
ence as a hospital pharmacist and having a postgraduate
diploma in clinical pharmacy, was trained to be a
prescriber. The pharmacist attended a prescribing
course which was accredited by the General
Pharmaceutical Council, UK as an Independent
Pharmacist Prescribing Course.25
Training included a minimum of 12 days of ‘period of
learning in practice’ under a ‘designated medical practi-
tioner’ (DMP), who was the consultant anaesthetist for
PAC. The training included case studies and sessions on
venous thromboembolism (VTE) prophylaxis with a con-
sultant vascular physician and the clinical nurse consult-
ant (CNC) for VTE prophylaxis at PAH. The DMP
endorsed the pharmacist’s competency to prescribe
before the study could start.
For the pilot, an amendment was facilitated to the
Queensland Health (Drugs and Poisons) Regulation 1996 to
allow ‘Pharmacists registered in Queensland who are
employed or contracted to Queensland Health and
working in the Pharmacist Prescribing Pilot’ to prescribe
controlled drugs, restricted drugs and schedule 2 and 3
poisons.
Intervention cohort
Patients were seen by a nurse, prescribing pharmacist,
Resident Medical Officer (RMO) and anaesthetist.
Patients had to be seen by the pharmacist before they
were seen by the RMO to allow usual RMO duties and a
countersignature of the pharmacist prescriptions, a site
requirement.
The pharmacist undertook all pharmacist duties as
per usual care, as well as prescribing medications on the
medication chart. The scope of prescribing was continu-
ing or withholding regular medications and prescribing
Figure 1 Randomisation flow
chart.
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VTE prophylaxis according to local and national guide-
lines, following a risk and contraindication assessment.26
Directors of surgery were consulted prior to the start
of the trial for permission to include patients in pre-
scribing of VTE prophylaxis, according to their specific
unit guidelines, which had been defined in advance in
collaboration with the CNC for VTE prophylaxis at PAH.
Urology and renal transplant patients were excluded
(N=43 control, N=34 intervention) from VTE prophy-
laxis prescribing as the director of urology was unavail-
able to confirm the scope of the project, and the
director for transplant requested exclusion on the
grounds that VTE prophylaxis in these patients was
driven more by consultant discretion as opposed to
being driven by guidelines.
Control cohort
Patients were seen by all four healthcare professionals in
clinic, in no particular order, as per usual care. Either
pharmacist in the clinic saw control patients for docu-
mentation of medication history. The prescribing of the
medication chart was the responsibility of the RMO. In
both arms, review and monitoring were undertaken, both
by RMOs in clinic at countersignature and by RMOs and
clinical pharmacists at the ward level, once the patient
was admitted. Changes made by RMOs to intervention
patient medication charts in clinic were recorded.
Outcome measures
The primary endpoint for the study was the accuracy of
medication charts, with regard to concordance of the
medication chart with the medication history, the plan for
medications perioperatively and the quality of the individ-
ual orders related to legality and safety for administration
purposes. The secondary endpoint was the appropriate-
ness of prescribing for both chemical and mechanical
VTE prophylaxis according to local and national
guidelines.26
Analysis of scanned copies of medication charts, for the
primary outcomes of omissions and errors, was conducted
in tandem by two assessors, one a member of the research
team and the other an external assessor, both trained in
the use of validated audit tools1 and blinded to randomisa-
tion. Any ambiguities were clarified by consensus.
Appropriateness of VTE prophylaxis prescribed in
both arms in clinic was analysed using scanned copies of
medication charts, in tandem by two assessors, one a
member of the research team and the other a CNC for
VTE prophylaxis at PAH. Prescribing was also assessed
on admission to the ward to ensure that VTE prophy-
laxis was appropriate.
An expert panel, comprising a surgeon, a clinical
pharmacologist, an anaesthetist, a RMO, a pharmacist
and a nurse, was convened to assess the clinical signifi-
cance of omissions in a randomly selected 5% sample of
the total cohort of patients from both arms (N=10
control, N=9 intervention). Panel members were
blinded to randomisation.
Tables 1 and 2 describe the collection methods and
definitions of these endpoints.
Categorical data were compared using χ² tests for
independence. When any one cell had a count of less
than 10, Fisher’s exact test was substituted. Logistic
regression was used to analyse the overall omissions
between the two groups. The number of regular and
‘PRN’ medications that the patient was currently
taking was included as an explanatory variable in the
model as it was deemed more likely that an individual
medication would be omitted in a patient taking a
large number of medications. Logistic regression was
also used to analyse the overall communications pre-
scribing errors between the two groups. The assump-
tion of independence between observations is clearly
violated as multiple observations exist for most
patients. As such, robust SEs clustered by patient were
calculated. No other covariates were adjusted for. All
reported p values are two-sided using a level of signifi-
cance of 0.05. All statistical analysis and sample size
calculations were conducted using Stata V.11.2
(StataCorp, College Station, Texas, USA).
Table 1 Analysis to assess the accuracy and safety of medication charts generated in the study
Measure Definition Method Assessing
Omissions Medication in patient’s medication
history not prescribed on medication
chart, with no reason documented
in patient chart
Every medication in patient’s
medication history checked
against medication chart—
omissions from medication chart
noted
Whether or not medication is
prescribed
Prescribing
errors
Anomaly in drug name, strength,
dose, frequency or route, with no
documentation in patient chart
Every medication in patient’s
medication history checked
against medication chart—
anomalies noted
Whether or not prescription is
accurate in terms of drug
name, strength, dose,
frequency and route
Communication
errors
Unclear prescription in terms of
name, route, dose, frequency, slow
release medication notification or
intermittent order prescribing
Every prescription written
checked using a validated tool—
unclear prescribing noted, as
agreed by both researchers
Whether or not prescription is
safe for administration
purposes
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RESULTS
The demographics of the patients randomised into the
trial were similar, except for the higher number of medica-
tions taken by patients in the control arm (see table 3).
Omissions
Total unintentional medication omissions from medica-
tion charts were higher for control patients (31.5%)
compared with interventions (1.2%) The OR for an
order in the control group to be omitted, compared
with that for the intervention group, was 41.0 (95% CI
20.6 to 81.8; p<0.001 logistic regression) after adjusting
for the number of medications the patient was currently
taking (see table 4 and figure 2). There were 59 prescri-
bers in the control arm, 54 of whom reviewed patients
who were currently taking regular or PRN medications
at home, and as such had the opportunity to omit a
patient’s medication. Of these 54 prescribers, the
median percentage of medications that were omitted
per prescriber in the control arm was 21 (range 0–100).
Clinical significance of omissions
Omissions from a randomly selected 5% of the total
cohort were evaluated for clinical significance. Of the 89
regular medications in the patients’ medication histories
in the control arm, 25 (28%) were omitted from the
medication charts, compared with 1 of 55 (2%) in the
control arm. When asked to assess the severity of omis-
sion, the average across the panel showed that 52% of
omissions in the control arm had the potential for
patient harm or ward inconvenience (see figure 3).
Only one reviewer thought the omission in the interven-
tion arm was significant.
Prescribing errors related to drug, dose and frequency
selection
Overall, 53 errors were identified where the drug
strength, dose or frequency prescribed did not match
the medication history or perioperative plan (see
figure 4). This equates to 6.3% of control orders com-
pared with 0.2% of intervention orders (p<0.001,
Fisher’s exact test).
Communication errors
Communication errors, where prescriptions were rated
as ambiguous or unclear, were significantly higher in the
control arm compared with the intervention arm. The
OR for an order in the control arm to have a communi-
cation error compared with an order in the intervention
Table 3 Characteristics of study population
Control Intervention
Total patients 190 194
Age* 57.6 (18–89) 55.8 (18–86)
Male (%) 58 59
Regular medications†‡ 4 (0–16) 3 (0–18)
When required ‘PRN’ medications†§ 2 (0–7) 1 (0–4)
Complementary and alternative medicines (CAM)† (0) (0–9) (0) (0–6)
Over the counter (OTC) medications† (0) (0–2) (0) (0–2)
Total medications 1364 983
Total medications (regular and PRN only) 1217 887
Medication charts prescribed 161 (85%) 194 (100%)
*Mean (range).
†Regular medications are defined as medications prescribed with the intent to be taken on a regular basis.
‡Median (range).
§Pro Re Nata (PRN) medications are defined as medications prescribed with the intent to be taken only when required.
Table 2 Analysis to assess accuracy of VTE risk and contraindication assessments and appropriateness of VTE prescribing
Measure Definition Method Assessing
VTE-risk
assessment
Patient categorised into low or
high risk for VTE, as per
guidelines
Every patient medical record
checked for a documented VTE risk
assessment
Risk assessment documented
Y/N
Risk assessment correct Y/N
VTE
contraindication
assessment
Patient highlighted as
inappropriate for mechanical
or chemical prophylaxis, as
per guidelines
Every patient medical record
checked for a documented
contraindication assessment
Contraindication assessment
documented Y/N
Contraindication assessment
correct Y/N
VTE prescribing Whether patient prescribed
mechanical and/or chemical
VTE prophylaxis, as per
guidelines
Prescribing of mechanical and
chemical VTE prophylaxis checked
against agreed local and national
guidelines
VTE prescribing appropriate
according to guidelines and
individual patient factors Y/N
VTE,venous thromboembolism.
Hale AR, Coombes ID, Stokes J, et al. BMJ Open 2013;3:e003027. doi:10.1136/bmjopen-2013-003027 5
Expanding the role of the preadmission clinic pharmacist
 group.bmj.com on July 11, 2013 - Published by bmjopen.bmj.comDownloaded from 
arm was 2.52 (95% CI 1.96 to 3.27; logistic regression
p<0.001). As there were multiple orders per patient,
robust SEs, clustered by patient, were utilised (see
table 5). Individually, communication errors were signifi-
cantly higher in the control arm for all types of error
except the route of administration (p=0.57 χ2 test).
From the control arm prescribers, 44 of them pre-
scribed medication on the medication charts, with a
median number of orders of 21 (range 1–85). The
median percentage of orders in the control arm that
contained at least one communication error per pre-
scriber was 38 (range 0–100).
VTE prophylaxis
Patients in the intervention arm were significantly more
likely than controls to have appropriate VTE prophylaxis
prescribed on the medication chart in PAC and to have
documented VTE assessment (see figure 5). On admis-
sion to the ward, approximately 90% of both interven-
tion and control patients were prescribed appropriate
VTE prophylaxis.
DISCUSSION
This study has built on the findings from previous
research of pharmacists prescribing in PAC settings,
which have found improved accuracy of information
gathered, and improved prescribing according to guide-
lines.9 27 Similar studies of pharmacist interventions in
different settings have shown improvements in clinical
endpoints such as blood pressure control, increased
appropriateness of prescribing and reductions in ADEs,
such as warfarin-associated bleeds.28 29
The traditional scope of practice for the PAC pharma-
cist consists of taking a medication history, using
Figure 2 Percentage of
medications omitted.
Table 4 Medication omissions from medication chart
Type of medication and perioperative plan Control (N) [%] Intervention (N) [%]
Regular
Continue 179 (805) [22.2] 3 (620) [0.5]
Withhold prior to surgery 46 (75) [7.4] 0 (48)
Withhold on morning of surgery 21 (54) [38.9] 0 (39)
Adjust dose 1 (5) [20.0] 0 (5)
Review 1 (7) [14.2] 0 (6)
Cease 0 (1) 0 (2)
PRN
Continue 128 (248) [51.6] 6 (142) [4.2]
Withhold prior to surgery 7 (12) [58.3] 2 (13) [15.4]
Adjust dose 0 (2) [20.0] 0 (1)
Review 0 (8) [14.3] 0 (11)
Total omissions 383 (1217) [31.5] 11 (887) [1.2]
Complementary and alternative medicines (CAMs)* 126 87
Over-the-counter medications (OTC)* 21 9
*CAM and OTC medications were not classed as omissions in either arm if they were not prescribed on the inpatient medication chart.
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guidelines, clinical judgement and referral to the surgi-
cal team to suggest a plan for medications periopera-
tively, and providing this information to the RMOs to
generate the medication charts. This scope has been
extended in our study by providing an appropriately
trained pharmacist to generate the medication chart
and prescribe VTE prophylaxis, which has led to a sig-
nificant reduction in omissions and prescribing errors,
ensuring that patients get the correct medication while
in hospital. The evaluation of VTE prophylaxis prescrib-
ing was essential to assess the safety and appropriateness
of initiation of a new medication, within guidelines, by
the prescribing pharmacist. The results from this study
have shown the prescribing to be as appropriate as usual
care at the time the patient is admitted to the ward.
Issues still remain with the prescribing, especially with
the use of inappropriate abbreviations.30 For example, a
large proportion of communication errors in the inter-
vention arm were due to the use of s/c to indicate sub-
cutaneous, which has informed the researchers on
future educational requirements of prescribers, espe-
cially with regard to safe prescribing.
Electronic prescribing may be one solution to such
errors involving legibility and inappropriate abbrevia-
tions, but studies have shown that the systems introduce
errors of their own.31 These errors need to be fully
assessed and appreciated if the quality of prescribing is
to be improved by the introduction of computerised pre-
scribing into the healthcare system.
The results presented in this paper are part of a larger
study. Further work is required to assess the appropriate-
ness of prescribing of medication charts and consumer
participation of this new model of care.23 There are a
number of limitations. Even though the trial was
Figure 3 Assessment of clinical
significance of omissions.
Figure 4 Number of prescribing
errors.
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randomised, the total number of medications that the
patients were taking was higher in the control arm
(1364) compared with the intervention arm (983). The
explanation for this is unknown but may in part be due
to large randomisation block sizes, possibly meaning
that a number of consecutive patients were randomised
to the control arm during clinic sessions, where patients
were more likely to have a higher burden of medication,
for example, during a vascular surgery clinic. There was
more opportunity for omissions from the control arm as
a result of more medications needing to be continued,
and this was allowed for in the analysis.
RMOs in clinic during the study were aware of the
intervention pharmacist’s role, which may have led to an
increased number and quality of medication charts
prescribed in the control arm. Even with this potential
effect, the study still showed a significant improvement
in the safety and accuracy of medication charts.
Review of medication orders is not a role that an
RMO routinely undertakes. All RMOs were educated
with regard to the requirement of a countersignature of
pharmacist orders, and to amend anything as required
prior to sign off. In the trial, 10 charts were amended—
5 changes were minor, 3 were addition of analgesics out
of the pharmacist’s prescribing scope and 2 changes
actually resulted in inappropriate VTE prophylaxis.
Despite the legislative changes, countersignature of
pharmacist orders was a local requirement owing to the
concern that junior doctors may become deskilled as a
result of being removed from the prescribing process.
Table 5 Prescribing errors with an ambiguity in at least one component of the prescription
Control number of errors (% of
total orders)
Intervention number of errors (% of
total orders) p Value
Total orders 1034 904
Orders with at least one
communication error
445 (43) 208 (23) <0.001*†
Prescribing communication errors 667 229
Prescribing communication errors
Drug name 23 (2.1) 0 <0.001‡
Route 79 (7.6) 76 (8.4) 0.57†
Dose 48 (4.6) 5 (0.6) <0.001‡
Frequency 190 (18.4) 96 (10.6) <0.001‡
Administration times incorrect or
missing
117 (14.9) (781 orders) 4 (0.5%) (762 orders) <0.001‡
PRN maximum dose missing 178 (74.5) (241 orders) 47 (32.6) (142 orders) <0.001‡
Slow release not specified 15 (30.0) (50 orders) 1 (1.5) (66 orders) <0.001‡
Intermittent order not specified 17 (57.5) (30 orders) 0 (38 orders) <0.001‡
*Logistic regression.
†χ2 test.
‡Fisher’s exact test.
Figure 5 Venous
thromboembolism prophylaxis
assessments and prescribing.
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However, the authors suggest that having an appropri-
ately trained prescribing pharmacist in clinic, for the
RMOs to use as guidance and to provide feedback on
any prescribing errors, may increase the effectiveness of
the learning environment.
Having only one pharmacist prescribing in the inter-
vention arm and multiple RMOs prescribing in the
control arm is a potential source of bias that is
unavoidable where individual knowledge, skills and
capabilities determine the quality of prescribing. It has
been suggested that medical undergraduate training
may not prepare graduates to prescribe, which if
addressed may reduce this individual variance.32 The
model of care tested in our study was successful as we
were able to reduce the variance within a group by
training one individual pharmacist to manage medica-
tions perioperatively, within a set scope of practice,
and to include prescribing. It could be argued that
the same results may have been obtained by providing
the RMOs with extra prescribing training, and that the
improved performance may not necessarily be solely
due to the introduction of a new professional discip-
line. The authors acknowledge that the improved
results may well be multifactorial, but would also
suggest that the underlying competencies of an experi-
enced, ‘advanced level’ pharmacist, plus the prescrib-
ing training provided, have ensured appropriate
competencies to prescribe in the model of care in
which the prescribing took place.33
The order of consultation in the intervention arm was
set by trial design. The order in the control arm was not
set, which is a true reflection of usual care, where the
patient could see the RMO prior to the pharmacist. This
may have impacted on the quality of control medication
charts prescribed by the RMO, without information
available from the pharmacist history. While this could
be classed as a limitation, this does reflect usual care in
PAC and highlights the collaborative nature of the exist-
ing model of care.
The prescribing pharmacist was able to see control
patients for usual care duties of a medication history,
which may be perceived as introducing bias. However, as
both pharmacists have received the same undergraduate
and general-level pharmacist training, the quality of
medication history gathered for the RMO to use to pre-
scribe the medication chart would be the same.
Another limitation is the potential sustainability of the
model of care, and capacity to train pharmacists as pre-
scribers. This was only one pharmacist in one hospital
who had received special training to be able to pre-
scribe. Evaluation of the requirements of non-medical
prescribing courses is underway, but substantial further
thought needs to be applied to ensure reproducibility of
these results in a larger sample and consistent produc-
tion of safe and effective prescribers.34
Further work is required to address the actual and per-
ceived medicolegal implications for both doctors and
pharmacists in such collaborations.
CONCLUSION
Medication charts in the intervention arm were signifi-
cantly safer and more accurate with regard to the
patients’ regular medications than medication charts in
the control arm.
There was no difference in appropriateness of VTE
prophylaxis prescribing between arms on admission to
the ward.
Our study has shown that the pharmacist in a PAC was
able to effectively gather all the information required to
collaboratively formulate a clinical decision in clinic
within an agreed scope of practice, and communicate the
decisions safely and accurately onto the medication chart.
A collaborative doctor–pharmacist prescribing model
in a PAC was as safe and accurate as usual care in ensur-
ing that patients were prescribed the medication
required on admission for elective surgery.
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